Combination of sapacitabine and HDAC inhibitors stimulates cell death in AML and other tumour types

SR Green*,1, AK Choudhary1 and IN Fleming1
1Cyclacel Ltd., 1 James Lindsay Place, Dundee DD1 5JJ, UK

BACKGROUND: Alternative treatments are needed for elderly patients with acute myeloid leukaemia, as the disease prognosis is poor and the current treatment is unsuitable for many patients.

METHODS: In this study, we investigated whether combining the nucleoside analogue sapacitabine with histone deacetylase (HDAC) inhibitors could be an effective treatment. Synergy and mode-of-action analysis were studied in cultured cell lines and the efficacy of the combination was confirmed in a xenograft model.

RESULTS: CNDAC (1-(2-C-cyano-2-deoxy-β-D-arabino-pentofuranosyl)-cytosine), the active component of sapacitabine, synergised with vorinostat in cell lines derived from a range of tumour types. Synergy was not dependent on a specific sequence of drug administration and was also observed when CNDAC was combined with an alternative HDAC inhibitor, valproate. Flow cytometry and western blot analysis confirmed that the combination induced a significant increase in apoptosis. Mode-of-action analysis detected changes in Bcl-xl, Mcl-1, Noxa, Bid and Bim, which are all regulators of the apoptotic process. The sapacitabine/vorinostat combination demonstrated significant benefit compared with the single-agent treatments in an MV4-11 xenograft, in the absence of any observed toxicity.

CONCLUSION: Sapacitabine and HDAC inhibitors are an effective drug combination that is worthy of clinical exploration.

Keywords: sapacitabine; nucleoside analogue; histone deacetylase inhibitor; vorinostat; valproate

Acute myeloid leukaemia (AML) is the most common type of acute leukaemia in adults, with ~12,000 cases diagnosed in the United States each year (Stone et al, 2004). Approximately two-thirds of these patients are older than 60 years; the prognosis for elderly AML patients is particularly poor, with a median survival of ~2 months and a 6% 2-year survival rate (Menzin et al, 2002). Conventional treatment for AML usually involves induction therapy comprising the combination of an anthracycline with the nucleoside analogue cytarabine. However, this treatment is very intensive and many elderly patients are considered unfit for induction treatment; accordingly there is a clear need for alternative treatments.

CNDAC (1-(2-C-cyano-2-deoxy-β-D-arabino-pentofuranosyl)-cytosine) is a 2′-deoxyctydine analogue that was designed specifically to have a novel DNA-strand-breaking mechanism of action (Matsuda et al, 1991). In contrast to other deoxycytidine analogues that block cells in the S-phase of the cell cycle (for example, gemcitabine and cytarabine), CNDAC induces an S-phase delay, followed by an arrest in G2. This effect is a function of the cyano group, which promotes the induction of single-strand (ss) DNA breaks after it has been integrated into DNA (Matsuda et al, 1991). These ssDNA breaks are converted into double-strand (ds) DNA breaks, which activate the dsDNA repair pathway and result in arrest at G2 (Liu et al, 2005). Sapacitabine (CS-682) is a palmitoyl derivative of CNDAC (Hanaoka et al, 1999). The fatty-acid side chain on the N4 group of the cytosine moiety improves oral bioavailability and reduces inactivation by deamination. Sapacitabine has improved efficacy over both gemcitabine and cytarabine in xenograft models (Tanaka et al, 1992; Hanaoka et al, 1999). Sapacitabine has completed phase I studies in solid tumours (Delaunoit et al, 2006; Gilbert et al, 2006) and haematological malignancies (Kantarjian et al, 2010) in which promising activity was reported. Sapacitabine is currently in phase II clinical trials in AML, myelodysplastic syndrome (MDS) and non-small-cell lung cancer (NSCLC).

Histone deacetylase (HDAC) inhibitors are a diverse series of compounds being developed as anti-cancer agents (Bolden et al, 2006). The HDAC inhibitors promote increased protein acetylation, particularly of histones. Increased acetylation has a dramatic effect on the conformation of histones and thereby the extent of DNA supercoiling; this results in changes in the cellular gene expression profile, by modulating access of transcription factors to their DNA-binding sites (Momparler, 2003; Duan et al, 2005). The failure of normal differentiation in haematological malignancies is often associated with poor transcription of genes involved in regulating the mature phenotype (Batty et al, 2009), suggesting that these diseases could be attractive targets for HDAC inhibitor treatment.

Sapacitabine has demonstrated clinical activity in a phase I study involving leukaemia patients (Kantarjian et al, 2010), whereas the HDAC inhibitors vorinostat and valproate have also
elicited clinical responses in AML patients in phase I studies (Bug et al, 2005; Garcia-Manero et al, 2008). In the clinic, most anti-cancer drugs are used as part of a combination therapy, to enhance efficacy, reduce toxicity and decrease drug resistance. Thus the pre-clinical evaluation of the combination of these two clinically active agents would determine whether the combination could be worth clinical exploration. As CNDAC (Liu et al, 2005) and most HDAC inhibitors (Bolden et al, 2006) promote increased apoptosis through very different mechanisms, it was hypothesised that a combination of these agents might significantly stimulate cell death. This hypothesis was evaluated by combining CNDAC with HDAC inhibitors in AML cell lines and in cell lines derived from other tumours. The cellular effects of this combination were investigated in the AML cell line, MV4-11. Finally, analysis of the combination in an MV4-11 mouse xenograft model demonstrated that combination treatment significantly reduced tumour growth compared with the single-agent treatment, confirming that the combination was an effective in vivo therapeutic option.

MATERIALS AND METHODS

Cell lines and reagents

MV4-11, Hut78, H460 and H1299 cells were purchased from ATCC (Mannassas, VA, USA); PL21 and HL60 cells were obtained from ECACC (Porton Down, UK); and Granta-519 cells were acquired from DSMZ (Braunschweig, Germany). Cell cultures were maintained as recommended by the suppliers. All reagents were purchased from Sigma (Poole, UK) unless stated otherwise.

Drug combination analysis

The cell lines were seeded in 96-well plates at the following cell densities: Granta-519, 25 000 cells per well; MV4-11, PL21 and Hut78, 8000 cells per well; HL60, 5000 cells per well; H460, 3000 cells per well; and H1299, 2000 cells per well. Stock solutions of CNDAC (Cyclacel Ltd., Dundee, UK) and vorinostat (Toronto Research Chemicals, North York, Canada) were prepared in dimethylsulphoxide. Valproate was dissolved in 0.9% (wt/vol) saline. The cell cycle profile was analysed by propidium iodide staining of ethanol-fixed cells as described previously (Fleming et al, 2008). The cell cycle profile was analysed by propidium iodide staining of ethanol-fixed cells as described previously (Fleming et al, 2008). The cell cycle profile was analysed by propidium iodide staining of ethanol-fixed cells as described previously (Fleming et al, 2008).

Flow cytometry assays

The cell cycle profile was analysed by propidium iodide staining of ethanol-fixed cells as described previously (Fleming et al, 2008). Cells were seeded and treated as for western blots.

The Bax/Bak activation assay was performed as described previously (Willis et al, 2005). Antibodies used in this experiment were: activated Bax (6A7, Santa Cruz Biotechnology), activated Bcl-2 (12D10, Cell Signalling, Hitchin, UK) and p53 (Oncogene, Nottingham, UK). Primary antibody incubations were carried out overnight at 4 °C in PBS containing 3% (wt/vol) dried milk, with the exception of PUMA, which was incubated in PBS containing 2% (wt/vol) bovine serum albumin. Membranes were washed three times in PBS, and then incubated for 1 h with the appropriate horseradish-peroxidase-conjugated secondary antibody (Pierce, Cramlington, UK) diluted in the ratio 1:6000 in PBS containing 3% (wt/vol) dried milk. Membranes were washed three times in PBS after antibody detection using ECL reagent (Amersham Corp., Little Chalfont, UK) or Immobilon HRP substrate (Millipore).

Western blot analysis

MV4-11 and HL60 cells were seeded in 10-cm plates at 9 × 10⁴ cells per plate, Hut78 cells at 1.4 × 10⁶ cells per plate and H460 cells at 6 × 10⁶ cells per plate. Cells were treated with various concentrations of CNDAC, vorinostat or a combination of these agents. After incubation, cells were harvested by centrifugation at 2000 r.p.m. for 5 min, washed once with ice-cold buffer A (50 mM HEPES (pH 7.0), containing 20 mM NaCl, 1 mM DTT, 10 mM sodium pyrophosphate, 10 mM sodium fluoride, 1 mM sodium orthovandate and protease inhibitors) and then resuspended in 150 μl of buffer A. All samples were lysed by sonication. Lysates (10 μg protein per well) were resolved on 12% acrylamide bis–tris gels (Invitrogen, Paisley, UK) and the proteins transferred to nitrocellulose membranes (Schleicher & Schuell, Dassel, Germany). Membranes were blocked for 1 h at room temperature in phosphate-buffered saline containing 0.02% (vol/vol) Tween 20 (PBST) and 5% (wt/vol) fat-free dried milk. Membranes were probed with the following primary antibodies: Noxa (Calbiochem, Nottingham, UK), Mcl-1 and Bcl-xl (Santa Cruz Biotechnology, Santa Cruz, CA, USA), survivin (Abcam, Cambridge, UK), histone H3 (AFFINITY, Mississauga, Canada), ECL reagent (Amersham Corp., Little Chalfont, UK) or Immobilon HRP substrate (Millipore).

In vivo studies

Female (nu/nu) mice were injected subcutaneously with 1 × 10⁶ MV4-11 cells resuspended in 50% Matrigel (BD Biosciences) at a single site on their flanks. Once tumour volumes were 126–256 mm³ (16 days post-implantation) animals were pair matched by tumour size into treatment groups (minimum of six mice per group) with a mean tumour size of ~190 mm³. Tumour measurements were calculated using the formula: volume (mm³) = width² (mm) × length (mm) × 0.5. Sapacitabine (Cyclacel Ltd.) was prepared in 2.5% dimethylacetate and 9.75% emulphor (PBST) and 5% (wt/vol) fat-free dried milk. Membranes were washed three times in PBS after antibody detection using ECL reagent (Amersham Corp., Little Chalfont, UK) or Immobilon HRP substrate (Millipore).
both the single-agent groups. Mice were weighed daily for 5 days of treatment and then at least twice a week to assess toxicity. No treatment-related deaths were seen in this experiment. The tumours were measured at least twice a week to determine tumour volume. The percent tumour growth inhibition (TGI) was determined using the formula: 1 – (mean change in treated tumour volume/mean change in control tumour volume) × 100. Statistical significance for the experiment was determined using a one-way analysis of variance (ANOVA) test. Significance between different treatment groups was determined using a two-sided unpaired Student’s t-test. Xenografts were performed at the Piedmont Research Centre. Studies were reviewed by an internal board to confirm that procedures complied with the recommendations of the Guide for Care and Use of Laboratory Animals.

RESULTS

In vitro drug combination analysis of CNDAC and HDAC inhibitors

The aim of this series of experiments was to determine whether combining CNDAC with HDAC inhibitors would produce a synergistic drug interaction. Initial evaluation of the combination was carried out in the AML cell lines MV4-11, HL60 and PL21. Combining CNDAC with either vorinostat (Table 1A) or valproate (Table 1B) generated CI values that represented predominantly either synergistic or additive drug interactions. Three treatment regimens were explored (CNDAC pre-treatment, HDAC inhibitor pre-treatment and concomitant treatment); CNDAC treatment before vorinostat generated slightly stronger synergy (lower CI values) than the other schedules tested. The CNDAC/valproate combination generated similar results with all three schedules tested.

These findings were expanded to include cell lines derived from other tumour types, including H460 and H1299 (NSCLC), Hut78 (cutaneous T-cell lymphoma) and Granta-519 (non-Hodgkin’s lymphoma). The CNDAC/vorinostat combination predominantly generated synergy in Hut78, Granta-519 and H1299 cells, whereas it produced a mostly additive drug interaction in H460 cells (Table 1A). Similarly, combination of CNDAC and valproate produced synergy in H1299 cells and weak synergy/additivity in H460 cells (Table 1B).

Overall, this series of results demonstrated that combining CNDAC with an HDAC inhibitor produced a synergistic increase in cytotoxicity in cell lines derived from diverse tumour types. Synergy was observed in cell types that contain either wild-type p53 (MV4-11, H460 and Granta-519) or mutant p53 (HL60, H1299 and Hut78), suggesting that the p53 status was not a critical factor for the combination. Moreover, combining CNDAC with either vorinostat or valproate produced broadly similar CI values in these cell lines, suggesting that the observed synergy was a class effect, and that the selection of the HDAC inhibitor did not appear to be particularly crucial.

| Cell line  | CNDAC pre-treatment | Vorinostat pre-treatment | Concomitant |
|------------|---------------------|--------------------------|-------------|
| MV4-11     | ED50: 1.19          | ED50: 0.87               | ED50: 1.04  |
|            | ED50: 0.86          | ED50: 0.77               | ED50: 0.86  |
|            | ED50: 0.68          | ED50: 0.73               | ED50: 0.77  |
|            |                     |                         |             |
| HL60       | ED50: 1.18          | ED50: 1.31               | ED50: 1.20  |
|            | ED50: 0.76          | ED50: 0.97               | ED50: 0.97  |
|            | ED50: 0.53          | ED50: 0.89               | ED50: 0.98  |
|            |                     |                         |             |
| PL21       | ED50: 0.99          | ED50: 1.12               | ED50: 1.29  |
|            | ED50: 0.71          | ED50: 0.87               | ED50: 0.73  |
|            | ED50: 0.53          | ED50: 0.70               | ED50: 0.73  |
|            |                     |                         |             |
| Hut78      | ED50: 0.66          | ED50: 0.64               | ED50: 0.99  |
|            | ED50: 0.56          | ED50: 0.47               | ED50: 0.51  |
|            | ED50: 0.48          | ED50: 0.36               | ED50: 0.76  |
|            |                     |                         |             |
| Granta-519 | ED50: 0.82          | ED50: 0.86               | ED50: 0.72  |
|            | ED50: 0.51          | ED50: 0.88               | ED50: 0.73  |
|            | ED50: 0.37          | ED50: 1.06               | ED50: 0.76  |
|            |                     |                         |             |
| H460       | ED50: 0.93          | ED50: 1.63               | ED50: 0.85  |
|            | ED50: 0.91          | ED50: 1.58               | ED50: 1.18  |
|            | ED50: 0.94          | ED50: 1.57               | ED50: 0.99  |
|            |                     |                         |             |
| H1299      | ED50: 2.24          | ED50: 0.66               | ED50: 0.63  |
|            | ED50: 0.42          | ED50: 0.84               | ED50: 0.59  |
|            | ED50: 0.60          | ED50: 1.90               | ED50: 0.99  |

Abbreviations: CNDAC = 1-(2-C-cyano-2-deoxy-ß-D-arabinofuranosyl)-cytosine; ED = effective dose. CNDAC was tested in combination with either vorinostat (A) or valproate (B) in various cell lines, using the protocol described in Materials and Methods. Concomitant and sequential treatment schedules were tested, and the resulting combination index (CI) values shown for ED50, ED75 and ED90 (the points on the curve where cellular proliferation is inhibited by 50, 75 and 90%, respectively). Results are the average of at least three independent experiments. The CI value definitions are as follows: 1.45 – 1.2 is moderately antagonistic, 1.2 – 1.1 is slightly antagonistic, 1.1 – 0.9 is additive, 0.9 – 0.85 is slightly synergistic, 0.85 – 0.7 is moderately synergistic and 0.7 – 0.3 is synergistic.
agents, different concentrations of drug (corresponding to 0.5 ×, 1 × and 2 × IC\textsubscript{50}) were evaluated during a 72-h incubation (Figure 1B). CNDAC and vorinostat single-agent treatments induced a dose-dependent increase in the sub-G1 cell population. Combination of CNDAC with vorinostat induced a significant increase in the sub-G1 cell population, compared with the single-agent treatments; this effect was also dose dependent. The induction of cell death was clearly synergistic when the compounds were used at either 0.5 × or 1 × IC\textsubscript{50} but only appeared additive when used at 2 × IC\textsubscript{50}: the apparent lack of synergy at 2 × IC\textsubscript{50} was presumably because of the fact that both single-agent treatments induced such a significant proportion of cell death on their own, making it difficult to evaluate synergy.

Finally, in this initial set of experiments, MV4-11 cells were treated with the CNDAC/vorinostat combination using the three treatment schedules evaluated in the cytotoxicity experiments to ascertain whether the sequence of compound administration had a significant influence on the amount of cell death. The results (Figure 1C) demonstrated that a synergistic increase in the sub-G1 cell population was seen for all three combination treatment schedules, but the CNDAC pre-treatment (42%) and the concomitant treatment (41%) induced a slightly higher proportion of cell death than the vorinostat pre-treatment (34%). This data correlated well with the CI values detected in the cytotoxicity experiments (Table 1A). These results indicated that the sequence of administration was not critical for the combination, and...
synergistic increase in cell death. The combination induced a
synergistic time-dependent increase in the level of full-length Bid,
which was enhanced by the combination with vorinostat (Figure 2),
suggesting that the induction of cell death involved the Bid
pathway. Another BH3-only protein, Bim, has three isoforms:
extra-long (EL), long (L) and short (S). Bim-S is constitutively
active, whereas Bim-EL and -L are regulated by reversible
phosphorylation (Wang et al, 2004; Shibue and Taniguchi, 2006).
All three isoforms of Bim were present in MV4-11 cells, and Bim-E
and -EL appeared to be composed of multiple bands. Both
vorinostat and the combination treatment enhanced the levels of
Bim-EL, consistent with previous vorinostat studies (Fandy
et al, 2005; Zhao et al, 2005). Combination treatment also increased
the electrophoretic mobility of Bim-EL (Figure 2). Such a mobility
shift is consistent with a change in a protein’s phosphorylation
state; several studies have reported that dephosphorylation of
Bim-EL increases its electrophoretic mobility and stimulates
apoptosis by allowing Bim-EL to directly bind to and activate
Bax (Harada et al, 2004; Wang et al, 2004). The observed changes in
the BH3-only proteins Noxa, Bid and Bim occurred before the
increase in cleaved PARP, suggesting that they contributed
towards the increased apoptosis. In contrast, the CNDAC/
vorinostat combination did not induce dephosphorylation of Bad
(data not shown), suggesting that the combination does not
activate the Bad pro-apoptotic pathway. The combination also
promoted a modest downregulation of the caspase inhibitor XIAP
(Figure 2), which would also contribute to enhanced apoptosis.
The pro-apoptotic Bcl-2 family proteins Bax and Bak are the key
drivers of apoptosis; when activated, these proteins permeabilize
the outer mitochondrial membrane and promote the release of
pro-apoptotic factors (for example, cytochrome c) that activate
caspases and initiate the apoptotic cascade. Western blot analysis
demonstrated that the combination did not increase the expression
of XIAP, whereas the upper band is an unknown protein. Results are representative of two
independent experiments.

Mode-of-action analysis of the CNDAC/vorinostat
combinations in MV4-11 cells

Western blot analysis was used to study the molecular changes that
were induced by the CNDAC/vorinostat combination (Figure 2).
Cells were initially treated with either CNDAC (C) or media (m) for
24 h before an equivalent volume of media being added, which
was either drug free (m) or contained vorinostat (V), and the
incubation continued for a further 8–24 h. As expected, vorinostat
stimulated an increase in histone acetylation. Similarly, CNDAC
enhanced p53 levels in MV4-11 cells, a property that has been
established for cytarabine (Kobayashi et al, 1998) and gemcitabine
(Achanta et al, 2001). The combination stimulated a modest
increase in histone H2AX phosphorylation at serine 139, over that
seen by either single agent. Phospho-H2AX is a marker of dsDNA
damage, but as this effect was relatively minor, it suggested that
enhancement of DNA damage was not the main cause of the
synergistic increase in cell death. The combination induced a
synergistic time-dependent increase in cleaved PARP, detectable
~16 h after adding vorinostat to CNDAC-treated cells (Figure 2).
A synergistic increase in the active cleaved form of caspase 3, an
executioner caspase, became evident at the same time as the
cleaved PARP. These two observations confirmed that the increase
in cells with a sub-G1 DNA content (Figure 1) was because of the
induction of apoptosis.

Apoptosis is regulated by the Bcl-2 family proteins and the
related BH3-only proteins. These proteins can be divided into two
groups, with either pro- or anti-apoptotic roles; modifying the
levels or activity of these proteins disrupts the cellular apoptotic
balance. Western blots confirmed that treatment with the CNDAC/
vorinostat combination reduced the levels of the anti-apoptotic
proteins Mcl-1 and Bcl-xl to a much greater degree than either
individual compound, but had no significant effect on Bcl-2
(Figure 2). Overall, the loss of Mcl-1 and Bcl-xl would push the
cells towards apoptosis. The BH3-only proteins are a family of
small pro-apoptotic proteins that connect various stress stimuli
with the Bcl-2 proteins (Shibue and Taniguchi, 2006). Western blot
analysis was used to study the effect of combination treatment on
Noxa and PUMA, as CNDAC upregulated p53 protein levels
(Figure 2) and these proteins are transcriptionally activated by p53
(Shibue and Taniguchi, 2006). CNDAC treatment induced both
Noxa and PUMA-α, whereas the combination induced a slightly
greater transient increase in Noxa, but had little effect on the levels
of PUMA-α (Figure 2). The BH3-only protein Bid has an important
role in apoptosis through a mechanism that involves its own
degradation (Shibue and Taniguchi, 2006). CNDAC treatment caused a
time-dependent decrease in the level of full-length Bid,
which was enhanced by the combination with vorinostat (Figure 2),
suggesting that the combination increases the levels of full-length Bid,
which was enhanced by the combination with vorinostat (Figure 2),
suggesting that the induction of cell death involved the Bid
pathway. Another BH3-only protein, Bim, has three isoforms:
extra-long (EL), long (L) and short (S). Bim-S is constitutively
active, whereas Bim-EL and -L are regulated by reversible
phosphorylation (Wang et al, 2004; Shibue and Taniguchi, 2006).
All three isoforms of Bim were present in MV4-11 cells, and Bim-E
and -EL appeared to be composed of multiple bands. Both
vorinostat and the combination treatment enhanced the levels of
Bim-EL, consistent with previous vorinostat studies (Fandy et al,
2005; Zhao et al, 2005). Combination treatment also increased
the electrophoretic mobility of Bim-EL (Figure 2). Such a mobility
shift is consistent with a change in a protein’s phosphorylation
state; several studies have reported that dephosphorylation of
Bim-EL increases its electrophoretic mobility and stimulates
apoptosis by allowing Bim-EL to directly bind to and activate
Bax (Harada et al, 2004; Wang et al, 2004). The observed changes in
the BH3-only proteins Noxa, Bid and Bim occurred before the
increase in cleaved PARP, suggesting that they contributed
towards the increased apoptosis. In contrast, the CNDAC/
vorinostat combination did not induce dephosphorylation of Bad
(data not shown), suggesting that the combination does not
activate the Bad pro-apoptotic pathway. The combination also
promoted a modest downregulation of the caspase inhibitor XIAP
(Figure 2), which would also contribute to enhanced apoptosis.
The pro-apoptotic Bcl-2 family proteins Bax and Bak are the key
drivers of apoptosis; when activated, these proteins permeabilize
the outer mitochondrial membrane and promote the release of
pro-apoptotic factors (for example, cytochrome c) that activate
caspases and initiate the apoptotic cascade. Western blot analysis
demonstrated that the combination did not increase the expression

Figure 2  Combination of CNDAC and vorinostat induces selective modulation of apoptotic proteins in MV4-11 cells. MV4-11 cells were treated with dimethylsulphoxide (m), 1 × IC50 CNDAC (C), 1 × IC50 vorinostat (V), or 1 × IC50 CNDAC and vorinostat (CV). The schedule involved 24-h CNDAC pre-treatment followed by vorinostat. Cells were harvested at 0, 8, 16 or 24 h after addition of vorinostat, as indicated. The resulting lysates (10 μg) were resolved on 12% acrylamide bis–tris gels, transferred to nitrocellulose membranes and probed with the antibodies shown. cPARP, cleaved PARP; cCaspase 3, active caspase 3.
of either of these proteins (data not shown); hence, a flow cytometry-based assay was performed to investigate whether the observed increase in apoptotic cells involved activation of Bax or Bak. When either Bax or Bak become activated, they undergo a conformational change, which reveals a neo-epitope that is recognised by specific antibodies. The antibodies are labelled with the FITC dye; hence, cells with increased FITC signal contain activated Bax or Bak. Some of the samples were incubated with secondary antibody in the absence of primary antibody (secondary Ab) to assess non-specific binding of the FITC secondary antibody. Results are the average ± s.d. of two independent experiments.

The combination of CNDAC and vorinostat can induce apoptosis in cell lines derived from different tumour types

As combining CNDAC with vorinostat produced a significant increase in the amount of apoptosis in MV4-11 cells (Figure 1), these studies were expanded to ascertain whether the observed cytotoxic synergy detected in other cell lines (Table 1) also involved the induction of apoptosis. HL60, Hut78 and H460 cells were chosen for further study, as they are from diverse tumour types and exhibited a range of CI values with the CNDAC/vorinostat combination. Based on the cytotoxicity data (Table 1) an appropriate treatment regimen was selected for each cell line. Cell cycle analysis demonstrated that combining CNDAC with vorinostat significantly increased the population of cells with a sub-G1 DNA content in HL60 and Hut78 cells and induced a modest sub-G1 increase in H460 cells (Figure 4A). A similar trend was observed by analysing the levels of cleaved PARP; combination treatment induced a significant increase in PARP cleavage in HL60 and Hut78 cells and a moderate increase in H460 cells, compared with the single-agent treatments (Figure 4B). These results were in general agreement with the combination analysis data and confirm that this combination appeared to be effective in cell lines derived from multiple tumour types.

In vivo evaluation of sapacitabine and vorinostat in combination

To determine whether these in vitro results translated into the in vivo setting, the combination was evaluated in an MV4-11 xenograft (Figure 5). The palmitoyl derivative CNDAC prodrug, sapacitabine, was used in vivo to maximise oral bioavailability. There were no treatment-related deaths during the experiment, suggesting that there was no adverse toxicity associated with the combination. In the control group, some mice were killed due to tumour burden (>1000 mm³) on day 14; hence, this was considered the experimental end point for statistical analysis. On day 14, the single-agent treatments appeared to have a reduced mean tumour size compared with the vehicle control (875 mm³). However, at the low doses evaluated in this experiment, the impact on tumour growth was relatively minimal, with all three single-agent treatment groups reaching the experimental end point by day 17. Unlike the single-agent treatments, combination of vorinostat with sapacitabine provided clear benefit throughout the course of the experiment. On Day 14, the sapacitabine (5 mg kg⁻¹) + vorinostat (33 mg kg⁻¹) group had a mean tumour volume of 245 mm³ and a TGI of 92%, whereas the sapacitabine (15 mg kg⁻¹) + vorinostat (33 mg kg⁻¹) group had a mean tumour volume of 107 mm³ and a TGI of 112%. An unpaired Student’s t-test demonstrated that both combination treatments were significantly different to the appropriate controls, which resulted in an overall highly significant one-way ANOVA test (P < 0.00001). These data demonstrate that there was a clear benefit of combining sapacitabine with vorinostat in this AML tumour model and that the combination was effective in vivo.

DISCUSSION

Conventional treatment for AML involves combination of an anthracycline with the nucleoside analogue cytarabine. However, the poor prognosis for AML patients in general, and elderly patients in particular (Menzin et al, 2002), means that alternative therapies are required. In this report, we investigated whether combining the novel nucleoside analogue CNDAC with HDAC inhibitors could be an effective treatment option. The resulting data provide compelling evidence that combining CNDAC with HDAC inhibitors produces an effective cytotoxic combination, both in vitro and in vivo. Moreover synergy was observed by combining CNDAC with either vorinostat or valproate, suggesting that there is a class effect between CNDAC and HDAC inhibitors.

Two distinct mechanisms can contribute towards synergy: inhibition of cell growth or induction of cell death. Evidence from multiple approaches demonstrated that the CNDAC/vorinostat combination stimulated a large increase in cell death, suggesting that this was making a significant contribution to the observed synergy. First, cell cycle analysis demonstrated that combination treatment induced a synergistic increase in cells with a sub-G1 DNA content (Figures 1 and 4); combining these agents killed approximately 50–70% of the MV4-11 cell population when treated at 1 × IC₅₀ for 72 h (Figure 1A and B). Second, the combination stimulated the conformational changes associated with activation of the pro-apoptotic proteins Bax and Bak (Figure 3), and increased the level of cleaved caspase 3 and cleaved PARP (Figure 2), providing clear evidence of an increase in apoptosis. Third, the data demonstrated that CNDAC synergised with HDAC inhibitors in diverse cell lines derived from both haematological malignancies and solid tumours (Table 1, Figures 1 and 4). These data demonstrate that the combination is effective in...
Synergy between sapacitabine and HDAC inhibitors
SR Green et al

Figure 4  The CNDAC/vorinostat combination stimulates apoptosis in cell lines derived from various tumour types. HL60, Hut78 and H460 cells were treated with 1 × IC50 CNDAC, vorinostat or both compounds. (A) Cell cycle profile of each cell line was analysed after propidium iodide staining. Treatment schedules were: HL60 cells, 24-h CNDAC pre-treatment followed by 16-h vorinostat treatment; Hut78 cells, 32-h concomitant treatment; H460 cells, 24-h CNDAC pre-treatment followed by 16-h vorinostat treatment. Results are the average of three independent experiments. (B) Cells were treated with dimethylsulphoxide (m), 1 × IC50 CNDAC (C), 1 × IC50 vorinostat (V) or 1 × IC50 CNDAC and vorinostat (CV). Treatment schedules were: HL60 cells, 24-h CNDAC pre-treatment followed by 16-h vorinostat treatment; Hut78 cells, 32-h concomitant treatment; H460 cells 24-h CNDAC pre-treatment followed by 48-h vorinostat treatment. The resulting lysates (20 μg) were resolved on 12% acrylamide bis–tris gels, transferred to nitrocellulose membranes and probed with cPARP antibody or an appropriate loading control (histone H2AX in HL60 and Hut78, actin in H460). Results are representative of two independent experiments. In HL60 cells, the IC50 values for CNDAC and vorinostat were 0.14 and 0.68 μm, respectively. In Hut78 cells, the IC50 values for CNDAC and vorinostat were 3.6 and 0.46 μm, respectively. In H460 cells, the IC50 values for CNDAC and vorinostat were 0.25 and 2.5 μm, respectively.

Figure 5  The effect of the combination of sapacitabine and vorinostat on the growth of an MV4-11 xenograft. Mice (nu/nu) were injected subcutaneously with ~ 1 × 107 MV4-11 cells per mouse at a single site on their flanks. Treatment was initiated when tumours were within the range 126–256 mm3 and was continued for up to 12 days. Results show mean tumour volume (± s.e.m.) for each treatment group (> 6 mice per group) and represent vehicle, sapacitabine (5 or 15 mg kg−1), vorinostat (33 mg kg−1), sapacitabine 5 vorinostat 33, sapacitabine 15 vorinostat 33.

a range of different tumour types and that the efficacy of the combination does not depend on a precise genetic signature. Previous studies have investigated whether combining HDAC inhibitors with nucleoside analogues stimulated apoptosis. Valproate enhanced the percentage of annexin V-positive cells induced by cytarabine treatment in cultured AML cells (Siitonen et al, 2005). Similarly, combining vorinostat with gemcitabine stimulated apoptosis in NSCLC (Rundall et al, 2005) and pancreatic cancer (Arnold et al, 2007) cell lines. None of these earlier combination studies delineated a molecular mechanism that could account for the observed increase in apoptosis. A recent review proposed several different mechanisms to explain synergy between HDAC inhibitors and other chemotherapeutic agents (Frew et al, 2009). The simplest hypothesis was that pre-treatment with an HDAC inhibitor increased the accessibility of DNA-damaging agents to their target by altering the chromatin structure, thus enhancing the cytotoxic effects. This hypothesis alone could not account for the synergy between CNDAC and vorinostat, as there was no schedule dependency for the combination (Figure 1C). A second hypothesis implied that HDAC inhibitors could synergise with DNA-damaging agents, either by inducing DNA damage themselves or suppressing the DNA repair process. It has been demonstrated that HDAC inhibitor treatment can induce rapid acetylation of histone proteins and phosphorylation of histone H2AX, followed by the appearance of cleaved PARP several hours later (Gaymes et al, 2006). In the data reported here, the combination of CNDAC with vorinostat only induced a modest increase in H2AX phosphorylation (Figure 2), which became evident at the same time as the cleaved PARP. These data suggest that the increase in H2AX phosphorylation was an early marker of cell death rather than an apoptotic stimulus, indicating that the synergy was not a result of the HDAC inhibitor contributing to effects on DNA damage/repair. A third potential mechanism behind the synergy was that HDAC inhibitors could sensitisise cells to the apoptotic effect of cytotoxic drugs by combining to decrease the cellular apoptotic threshold, through altered expression of key apoptotic regulators (Frew et al, 2009). As discussed below, the data presented herein are consistent with this hypothesis.
Bak and Bax are the key drivers of apoptosis. Active Bak and Bax permeabilize the mitochondrial outer membrane, releasing pro-apoptotic proteins such as cytochrome c and Smac/DIABLO into the cytosol, where they initiate and promote caspase activation. The Bak and Bax activity is regulated by a complex interplay between the anti-apoptotic Bcl-2 family members and the pro-apoptotic BH3-only proteins. Recent studies have revealed that the Bcl-2 family proteins only bind certain BH3-only proteins (Shibue and Taniguchi, 2006); Bcl-2 interacts with Bad, Bim or PUMA; Bcl-xL binds Bad, Bid, Bim or PUMA; and Mcl-1 is regulated by Bim, PUMA or Noxa. The combination of CNDAC and vorinostat produced discernable changes in the levels of a number of the proteins that regulate apoptosis, including decreases in the anti-apoptotic proteins Mcl-1 and Bcl-xL, and increases in the levels or activation state of the pro-apoptotic BH3-only proteins Noxa, Bid and Bim-EL (Figure 2). Modest molecular changes in all of these proteins were caused by CNDAC and/or vorinostat single-agent treatments, which suggested that the observed synergy was probably a result of the concerted action of the two agents on the apoptotic proteins. These changes would significantly disrupt the interplay between the apoptotic regulatory proteins causing the resultant activation of Bak and Bax and the induction of apoptosis.

Recent combination studies have suggested that targeting multiple arms of the apoptotic regulatory machinery is an effective strategy for killing cells (Chen et al., 2007; Rosato et al., 2007). Drug combinations that target Mcl-1 and Bcl-2/Bcl-xL may mimic the actions of more physiological regulators of apoptosis (Dai and Grant, 2007), and selective targeting of multiple apoptotic pathways may overcome functional redundancy and force cells into apoptosis. The in vitro studies presented here are consistent with this hypothesis; the CNDAC/vorinostat combination (Table 1 and Figure 1) targets multiple arms of the apoptotic machinery, producing changes in the levels of key proteins involved in regulating apoptosis (Figures 2–4).

Based on the promising in vitro data, the studies were expanded into an in vivo MV4-11 xenograft model. The doses of both agents were significantly below the previously reported maximum tolerated doses (Hanaoka et al., 1999; Butler et al., 2000) and, as would be expected, showed minimal efficacy when used as single agents (Figure 5). However, the combination resulted in significantly improved efficacy, including regressions in a number of tumours at the higher dose levels tested. Moreover, the relatively low doses of drug used meant that there was no associated toxicity or weight loss in either of the single-agent arms or the combination groups. Maximum mean weight loss for a group was < 4%. Although there was tumour re-growth once the dosing ceased, treatment could have been continued for additional cycles, as the agents were so well tolerated. The results of the MV4-11 xenograft confirmed that the promising in vitro synergy translated into the in vivo setting.

Owing to the limitations of the available therapy, there is an urgent need for new therapeutic options for AML patients, particularly those aged ≥ 70. Currently, both sapacitabine and vorinostat are being evaluated in clinical studies, and have reported single-agent activity in phase I studies in AML and MDS patients (Garcia-Manero et al., 2008; Kantarjian et al., 2010). Sapacitabine is being explored because of the well-established activity of cytosine analogues such as cytarabine in myeloid diseases. The HDAC inhibitors may be a good option, because in myeloid malignancies, failure of normal differentiation often results from an inability to transcribe genes that encode proteins that either mediate or define the mature phenotype (Batty et al., 2009). For optimal transcription of these genes, histones should be in a maximally acetylated state; hence, HDAC inhibitors could provide a good therapeutic strategy for treating AML and other haematological malignancies. The data reported herein suggest that exploring the combination of sapacitabine and vorinostat in the clinic would be a valid option, especially if they could be used at reduced doses while maintaining improved efficacy.

ACKNOWLEDGEMENTS

This study was financially supported by Cyclacel Ltd. We are very grateful for Dr David MacCallum’s help with the Bax/bak activation flow cytometry experiments and colleagues at Cyclacel for insightful discussions and critical reading of this paper.

REFERENCES

Achanta G, Pelicano H, Feng L, Plunkett W, Huang P (2001) Interaction of p53 and DNA-PK in response to nucleoside analogues: potential role as a sensor complex for DNA damage. Cancer Res 61: 8723–8729
Arnold NB, Arkus N, Gunn J, Korc M (2007) The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer. Clin Cancer Res 13: 18–26
Batty N, Malouf GG, Issa JP (2009) Histone deacetylase inhibitors as anti-neoplastic agents. Cancer Lett 280: 192–200
Borden JE, Pearl MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769–784
Bug G, Ritter M, Wassmann B, Schoch C, Heinzel T, Schwarz K, Romsanski A, Kramer OH, Kampfmann M, Hoelder D, Neubauer A, Ruthardt M, Ottmann OG (2005) Clinical trial of valproic acid, an inhibitor of histone deacetylase, in patients with advanced leukemias and myelodysplastic syndromes. Invest New Drugs 24: 327–333
Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C, Thaler HT, Rifkind RA, Marks PA, Richon VM (2000) Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 60: 5165–5170
Chen S, Dai Y, Harada H, Dent P, Grant S (2007) Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res 67: 792–791
Dai Y, Grant S (2007) Targeting multiple arms of the apoptotic regulatory machinery. Cancer Res 67: 2908–2911
Delaunoy T, Burch PA, Reid JM, Camoriano JK, Kobayash T, Braich T, Kaur JS, Rubin J, Erlichman C (2006) A phase I clinical and pharmacokinetic study of CS-682 administered orally in advanced malignant solid tumours. Invest New Drugs 24: 327–333
Duan H, Heckman CA, Boxer LM (2005) Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas. Mol Cell Biol 25: 1608–1619
Fandy TE, Shankar S, Ross DD, Saussville E, Srivastava RK (2005) Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. Neoplasia 7: 646–657
Fleming IN, Hogben M, Frame S, McClue SJ, Green SR (2008) Synergistic inhibition of ErbB signaling by combined treatment with Seliciclib and ErbB-targeting agents. Clin Cancer Res 14: 4326–4335
Frew AJ, Johnstone RW, Borden JE (2009) Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett 280: 125–133
Garcia-Manero G, Yang H, Rueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG, Faderl S, Koller C, Morris G, Rosner G, Loboda A, Fantin VR, Randolph SS, Hardwick JS, Reilly JF, Chen C, Ricker JL, Sciscio JP, Richon VM, Frankel SR, Kantarjian HM (2008) Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid (SAHA)) in patients with advanced leukaemias and myelodysplastic syndromes. Blood 111: 1060–1066
Gaymes TJ, Padua RA, Pla M, Orr S, Omidvar N, Chomienne C, Mufti GJ, Rassool FV (2006) Histone deacetylase inhibitors (HDACi) cause
DNA damage in leukemia cells: a mechanism for leukemia-specific HDI-dependent apoptosis. Mol Cancer Res 4: 563–573

Gilbert J, Carducci MA, Baker SD, Dees EC, Donehower R (2006) A Phase I study of the oral antimitabolite, CS-682, administered once daily 5 days per week in patients with refractory solid tumour malignancies. Invest New Drugs 24: 499–508

Hanaoka K, Suzuki M, Kobayashi T, Tanzawa F, Tanaka K, Shibayama T, Miura S, Itoka T, Iwabuchi H, Nakagawa A, Mitsuhashi Y, Hisaoka M, Kaneko M, Tomida A, Wataya Y, Nomura T, Sasaki T, Matsuda A, Tsuruo T, Kurakata S (1999) Antitumour activity and novel DNA-self-strand-breaking mechanism of CNDAC (1-(2-C-cyano-2-deoxy-beta-D-arabinopyranosyl)cytosine) and its N4-palmitoyl derivative (CS-682). Int J Cancer 82: 226–236

Harada H, Quearry B, Ruiz-Vela A, Korsmeyer SJ (2004) Survival factor-induced extracellular signal-regulated kinase phosphorylates BIM, inhibiting its association with BAX and proapoptotic activity. Proc Natl Acad Sci USA 101: 15313–15317

Kantarjian H, Garcia-Manero G, O’Brien S, Faderl S, Ravandi F, Westwood R, Green SR, Chiao JH, Boone PA, Cortes J, Plunkett W (2010) Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome. J Clin Oncol 28: 285–291

Kobayashi T, Ruan S, Jabbur JR, Consoli U, Clodi K, Shiku H, Owen-Schaub LB, Andreeff M, Reed JC, Zhang W (1998) Differential p53 phosphorylation and activation of apoptosis-promoting genes Bax and Fas/ Apo-1 by irradiation and ara-C treatment. Cell Death Differ 5: 584–591

Liu X, Guo Y, Li Y, Jiang Y, Chubb S, Azuma A, Huang P, Matsuda A, Hittelman W, Plunkett W (2005) Molecular basis for G2 arrest induced by 2′-C-cyano-2′-deoxy-1-beta-D-arabinofuranosylcytosine and consequences of checkpoint abrogation. Cancer Res 65: 6874–6881

Matsuda A, Nakajima Y, Azuma A, Tanaka M, Sasaki T (1991) Nucleosides and nucleotides. 100. 2′,2′-C-cyano-2′-deoxy-1-beta-D-arabinofuranosyl-cytosine (CNDAC); design of a potential mechanism-based DNA-strand-breaking antineoplastic nucleoside. J Med Chem 34: 2917–2919

Menzin J, Lang K, Earle CC, Kerney D, Mallick R (2002) The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med 162: 1597–1603

Momparler RL (2003) Cancer epigenetics. Oncogene 22: 6479–6483

Rosato RR, Almenara JA, Coe S, Grant S (2007) Themultikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Cancer Res 67: 9490–9500

Rundall BK, Denlinger CE, Jones DR (2005) Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non-small cell lung cancer. Surgery 138: 360–367

Siitonen T, Koistinen P, Savolainen ER (2005) Increase in Ara-C cytotoxicity in the presence of valproate, a histone deacetylase inhibitor, is associated with the concurrent expression of cyclin D1 and p27(Kip1) in acute myeloblastic leukemia cells. Leuk Res 29: 1335–1342

Stone RM, O’Donnell MR, Sekeres MA (2004) Acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 1: 98–117

Tanaka M, Matsuda A, Terao T, Sasaki T (1992) Antitumour activity of a novel nucleoside, 2′,2′-C-cyano-2′-deoxy-1-beta-D-arabinofuranosylcytosine (CNDAC) against murine and human tumours. Cancer Lett 64: 67–74

Wang P, Gilmore AP, Streuli CH (2004) Bim is an apoptosis sensor that responds to loss of survival signals delivered by epidermal growth factor but not those provided by integrins. J Biol Chem 279: 41280–41285

Willis SN, Chen L, Dawson G, Wei A, Naik E, Fletcher JL, Adams JM, Huang DC (2005) Proapoptotic BAK is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 19: 1294–1305

Zhao Y, Tan J, Zhuang L, Jiang X, Liu ET, Yu Q (2005) Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc Natl Acad Sci USA 102: 16090–16095